EU's CHMP endorses Nycomed's Daxas
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that Nycomed's oral phosphodiesterase-4 inhibitor Daxas (roflumilast) be approved for the treatment for chronic obstructive pulmonary disease (COPD).